Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Coagulation01:09

Coagulation

7.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.4K
Introduction to Hemostasis01:05

Introduction to Hemostasis

8.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ruthenium Compounds Differentially Inhibit Group IA and IIA Snake Venom Phospholipase A<sub>2</sub> Anticoagulant Activity.

International journal of molecular sciences·2026
Same author

Procoagulant Effects of <i>Bothrops diporus</i> Venom: Kinetic Modeling and Role of Serine Protease Activity.

International journal of molecular sciences·2025
Same author

Carbon Monoxide or Ruthenium: Will the Real Modulator of Coagulation and Fibrinolysis Please Stand Up!

International journal of molecular sciences·2025
Same author

Rattlesnake Roundup: Point-of-Care Thrombelastographic Methods Define the Molecular Impacts on Coagulation of <i>Crotalus</i> Venom Toxins In Vitro and In Vivo.

Toxins·2025
Same author

Antivenom Administration After Rattlesnake Envenoming in Arizona Does Not Directly Diminish Pain.

Toxins·2024
Same author

Ruthenium Antivenom Inhibits the Defibrinogenating Activity of <i>Crotalus adamanteus</i> Venom in Rabbits.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Sep 10, 2025

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

8.9K

Special Issue "Advances in Coagulation and Anticoagulation".

Vance G Nielsen1

  • 1Department of Anesthesiology, The University of Arizona College of Medicine, Tucson, AZ 85724, USA.

International Journal of Molecular Sciences
|August 28, 2025
PubMed
Summary

Molecular investigations into coagulopathy mechanisms are crucial for advancing clinical care in hemorrhagic and thrombotic diseases. Understanding these processes improves patient outcomes and treatment strategies for bleeding and clotting disorders.

More Related Videos

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

844
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.6K

Related Experiment Videos

Last Updated: Sep 10, 2025

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

8.9K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

844
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.6K

Area of Science:

  • Hematology
  • Molecular Biology
  • Clinical Medicine

Background:

  • Hemorrhagic and thrombotic diseases require a deep understanding of the coagulation cascade.
  • Molecular mechanisms underlying coagulopathy are complex and multifactorial.
  • Current clinical care advancements depend on continuous research into hemostasis and thrombosis.

Discussion:

  • Investigating the molecular basis of coagulopathy is essential for developing targeted therapies.
  • Understanding genetic and acquired factors influencing blood clotting is key.
  • Translational research bridges molecular findings with clinical applications.

Key Insights:

  • Detailed molecular insights into coagulopathy drive innovation in patient care.
  • Research into coagulation pathways offers potential for novel diagnostic and therapeutic strategies.
  • The study of molecular mechanisms directly impacts the management of bleeding and clotting disorders.

Outlook:

  • Future research will likely focus on personalized medicine approaches for coagulopathies.
  • Advancements in molecular diagnostics will enable earlier and more accurate disease detection.
  • Continued exploration of coagulopathy mechanisms promises improved patient outcomes and reduced disease burden.